The purpose of this proposal is to develop, validate and integrate novel biomarkers to characterize the risk of getting, having, or progressing with breast cancer. We have assembled a superb multidisciplinary team of academic and industry investigators who are using molecular and cell based technologies for biomarker development. We will further develop and evaluate them using powerful clinical resources, including unique retrospective and prospective data sets, and will integrate them with each other (cross validation) and into the context of clinical decision (modeling). The proposed studies attempt to redefine the paradigm from conventional breast cancer screening to combined detection/biological characterization/risk projection. Our hypotheses are that: 1) SNP (germline) and proteomic (serum) profiles can define breast cancer risk and detect early cancer, and may be combined for a tiered screening strategy; 2) Promising biomarkers indicative of risk of progression and metastasis, including tissue-based expression profiling and detection of circulating tumor cells (CTCs), should be directly compared as well as integrated to maximize information about phenotypes and risk; and 3) Combined analysis of biomarkers is not only more efficient but may lead to integrated strategies for optimal clinical application. In order to accomplish our work we propose 4 projects: Project 1: Develop SNP- and serum proteomics-based profiles for cancer detection (primary and secondary) and risk profiling in the context of clinical evaluation of palpable and mammographic abnormalities; Project 2: Develop paraffin based expression profiles to predict risk of disease progression using retrospective datasets (Guy's Hospital: natural history population with 25 yr follow-up and no systemic therapy; UCSF comprehensive micrometastases/CTC data set; UCSF SPORE DCIS data set); Project 3: Develop and validate CTC-based assays, including leading approaches for CTC detection; cross-validate CTC data with tissue-based biomarkers; and develop methods for molecular profiling of CTCs; Project 4: Evaluate promising biomarkers in a prospective clinical study for cross validation of assays and integration into predictive outcome models that reflect the biological properties of the cancer detected. ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O1))
Program Officer
Patriotis, Christos F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Marks, Jeffrey R; Anderson, Karen S; Engstrom, Paul et al. (2015) Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev 24:435-41
Magbanua, Mark Jesus M; Sosa, Eduardo V; Roy, Ritu et al. (2013) Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 73:30-40
Magbanua, Mark Jesus M; Park, John W (2013) Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods 64:114-8
Magbanua, Mark Jesus M; Sosa, Eduardo V; Scott, Janet H et al. (2012) Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 12:78
Petrillo, Laura A; Wolf, Denise M; Kapoun, Ann M et al. (2012) Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat 135:913-22
Esserman, Laura J; Moore, Dan H; Tsing, Pamela J et al. (2011) Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 129:607-16
Yau, Christina; Wang, Yixin; Zhang, Yi et al. (2011) Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat 126:803-10
Esserman, Laura J; Shieh, Yiwey; Rutgers, Emiel J T et al. (2011) Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 130:725-34
Yau, Christina; Esserman, Laura; Moore, Dan H et al. (2010) A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12:R85

Showing the most recent 10 out of 14 publications